Clinical Trial Update: Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety and maximum tolerated dose of BAY1000394 given in a 4 weeks on/2 weeks off schedule in patients with advanced cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• BAY1000394 (BAY1000394)

Snippet

Sponsor: Bayer | Conditions: Neoplasms | Phase 1 | Status: COMPLETED